Page last updated: 2024-11-07

dodecyloctaethyleneglycol monoether

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

octaethyleneglycol monododecyl ether : The hydroxypolyether that is octaethylene glycol in which one of the hydroxy groups is substituted by dodecyloxy. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID123921
CHEMBL ID501722
CHEBI ID41527
SCHEMBL ID60924
MeSH IDM0067914

Synonyms (31)

Synonym
octaethylene glycol monododecyl ether, >=98% (gc)
o-dodecanyl octaethylene glycol
3,6,9,12,15,18,21,24-octaoxahexatriacontan-1-ol
CHEBI:41527 ,
n-dodecyl octaethylene glycol monoether
octaethyleneglycol monododecyl ether
octaethyleneglycol-dodecylmonoether
3055-98-9
dodecyloctaethyleneglycol monoether
2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol
octaethylene glycol monododecyl ether
O0139
CHEMBL501722
c-12-e-8
dodecyl octaethylene glycol ether
c12e8
SCHEMBL60924
octaethylene glycol mono-n-dodecyl ether
AKOS028110805
octaethylene glycol monododecyl ether, bioxtra, >=98.0% (gc)
DTXSID30184640
mfcd00043234
J-018015
FT-0757710
81208-94-8
Q7076696
T72266
octaethyleneglycol mono-n-dodecyl ether
AS-55840
CS-0173452
HY-138941
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydroxypolyetherA hydroxyether compound containing more than one ether group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID362078Growth inhibition of human MOLT4 cells after 5 days by MTT assay2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Selective inhibitory effects of hybrid liposomes on the growth of HIV type 1-infected cells in vitro.
AID362079Growth inhibition of HIV1 3B infected human MOLT4 cells after 5 days by MTT assay2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Selective inhibitory effects of hybrid liposomes on the growth of HIV type 1-infected cells in vitro.
AID362080Selectivity index, ratio of IC50 for HIV 3B infected cells to IC50 for human MOLT4 cells2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Selective inhibitory effects of hybrid liposomes on the growth of HIV type 1-infected cells in vitro.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (77)

TimeframeStudies, This Drug (%)All Drugs %
pre-199030 (38.96)18.7374
1990's20 (25.97)18.2507
2000's14 (18.18)29.6817
2010's12 (15.58)24.3611
2020's1 (1.30)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.92 (24.57)
Research Supply Index4.39 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other79 (98.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]